Tagged with Opinion,

Opinion Rare diseases and cell and gene therapy executive recruitment specialist Steve Smith outlines six key strategies for attracting and retaining talent in these rapidly emerging fields.   In a young industry experiencing rapid growth, talent demand far outweighs supply Cell & Gene Therapy; “It’s no longer something people read about…

Opinion Frost & Sullivan’s Senior Research Analyst, Aarti Chitale looks at the sizeable impact that precision medicine, especially regenerative medicine, is already having on the global therapeutic landscape, and how the Asia-Pacific region is positioning itself at the forefront of this trend.   Providing the right treatment/ right drug at the…

Opinion Veeva Systems Europe’s Paul Attridge highlights how a switch to a continuous model for regulatory operations could allow biopharmaceutical companies to submit high-quality regulatory submissions for their products faster than ever before.   Like continuous manufacturing, which is widely employed in other industries and is starting to show signs of…

USA PwC’s Kelly Barnes examines how the US pharmaceutical sector is having to rethink its relationship with consumers, experimenting with new and innovative pricing models, and adopting a more holistic view of the patients using their medicines.   American consumers want more than just lower prices from pharmaceutical companies US Consumers…

Vaccines MSD’s Cyril Schiever outlines why vaccine hesitancy is such a threat to global health, the misinformation around vaccines being spread online, and how multi-stakeholder collaboration can help counter this emerging problem.   The World Health Organization (WHO) recently identified vaccine hesitancy as one of the top 10 global health threats…

Brazil Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves and their organizations.   What are the qualities you look for in a Country Manager? Capable leaders are those who…

USA Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry.   Biotech [is the] new frontier for US-China tensions The G20 gathering in Osaka at the end of June was, overall, less tense than other multilateral fora over the…

Opinion Ulrich Neumann of Certara outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make on the global biopharma industry.   While the collection of real-world data is not new, real-world evidence is poised to have a profound impact on the biopharma industry…

USA Chip Davis of the Association for Accessible Medicines argues that learning from the European biosimilars approval experience could speed up patient access to these complex drugs in the USA.   Advancements in biologic research and development have brought forth life-saving treatments for patients with cancer as well as such chronic…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in the cell and gene therapy market for investments and deal activities.   Background Cell and gene therapies hold the promise of bringing significant clinical benefits to patients by directly targeting the underlying cause of disease. With tremendous…

USA US industry veteran Sharon Ayd describes her journey to becoming a pharma company board member, the various hurdles still facing female pharma executives, and the responsibility of women at the top to “pay it back” and help the next generation of female leaders.   As I climbed the corporate ladder,…

Opinion Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which…